Navigation Links
Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Date:2/8/2008

- Study Achieves Primary Efficacy Endpoint and Demonstrates Improved

Quality of Sleep -

LAVAL, QC, Feb. 8 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that its recently completed North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001) achieved statistical significance for the primary efficacy endpoint (p value of 0.0183). The study also demonstrated significantly improved patient sleep patterns in favour of trazodone. Labopharm plans to file a New Drug Application (NDA) for its once-daily formulation of trazodone with the U.S. Food and Drug Administration later this year.

"The positive results of this study not only demonstrate the efficacy and safety of our once-daily formulation, but also the ability of our formulation to significantly improve the overall quality of sleep - there was significantly less awakening at night," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "It is recognized that a major challenge in treating depression is having patients comply with taking their medication due to slow onset of action and exacerbation of sleep disturbance and agitation. As a result, a once-daily depression treatment that also reduces agitation and improves quality of sleep, thus reducing the need for add-on therapies, should be well positioned in the antidepressant marketplace. We believe that our once-daily trazodone formulation is such a treatment."

Results of the Study

Study 04ACL3-001 is a randomized, double-blind, two-arm, multi-centre study comparing the efficacy and safety of Labopharm's once-daily trazodone formulation to placebo, in patients with major unipolar depressive disorder, over an eight-week period. In the study, 412 patients were randomized to treatment with Labopharm's once-daily trazodone, or placebo. Within the initial two-week titration period, pa
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
2. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
3. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
4. Labopharm Reports Results for Third Quarter Fiscal 2007
5. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
6. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
7. Labopharm appeals FDAs decision on once-daily tramadol
8. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
9. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
10. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
11. CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...researchers remain cautious about future antibioti...RIDAY, Nov. 21 (HealthDay News) -- People with mod...ase (COPD) may be able to reduce the frequency of ...mon antibiotic, a new report says. , The study... American Journal of Respiratory and Critical Car...
(Date:11/21/2008)...TON, Nov. 21 The Unive...d the beginning of a collaborative effort to eradi...ip for Breast Cancer Awareness and Research of the...irst Lady of the United States, and Vivian Fernand... Joining M. D. Anderson in the initiative are th...
(Date:11/21/2008)...% Shareholders Intend To Vigorously Protect Invest...INNATI, Nov. 21 Dr. Ste...ed an amendment to their Schedule 13D with the U.S...reviously filed a 13D disclosing ownership of 11.4...rates 77 LasikPlus fixed-site laser vision correct...
(Date:11/21/2008)...KLIN LAKES, N.J., Nov. 21 /PRNewswire-FirstCall/ -...or medical intervention in treating 88 percent of ...cent of Americans treated for a chronic condition ...ending and 75 percent of all medical costs. A pro...ears by Medco Health Solutions, Inc. (NYSE: MHS ...
Breaking Medicine News(10 mins):Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6
...cording to American research, the most effective w...ysiology . Lead author David Ludwig, director of ...Hospital Boston, who says that 'This study shows t...l', also notes that heavy people with an apple sha...
...new study of chemo patients, scientists at the Geo...r Institute has revealed that a gene , p53, though...cer cells, may actually help them thrive. The res...bjects whose tumors had mutations in the gene p53 ...
...new study has shown that cigarette smoking is more...hol consumption . The study, published in the Jo...t a quarter of head and neck cancers among non-dri...g. Led by Dr. Mia Hashibe of the International A...
...new study by researchers from the National Evoluti...US, has revealed how reproductive speed prevents ...hat are regularly hunted by humans, from becoming ...ough habitat loss and living in a limited geograph...
Other Medicine News:Health News:Check Your Physiology Before You Choose A Diet 2Health News:Gene Thought to Help Kill Cancer Cells may Actually Help Them Thrive 2Health News:Extinction Risk of Grazing Animals Depends on Reproductive Speed 2
(Date:11/20/2008)...ewswire/ -- The following is being released by Cen...AT: World AIDS Day Audio Media Conference , ... 11:00 a.m. EST , Call-in number: 1-800-949-847...talk.com/r/1xe41i2yre8rs , , WHY: With n...ewly put on treatment worldwide, advocates are cal...
(Date:11/20/2008)...A, Nov. 20 GlaxoSmithKlin...tates Food and Drug Administration (FDA) granted a...for the treatment of thrombocytopenia in patients ...purpura (ITP) who have had an insufficient respons...my. The approval is a significant milestone for PR...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...wire-FirstCall/ -- Bionovo, Inc.,(Nasdaq: BNVI ...the Phase 1B,clinical trial of their lead drug ca...L101, at the Society for Integrative Oncology,s Fi... The Company,s oral presentation was selected,as... part of the Best of the,SIO Session on November ...
Breaking Medicine Technology:Faith and Civil Society Leaders Call for Truth and Leadership in U.S. HIV Prevention Efforts 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5New surgery improves head and neck cancer treatment 3113 1New surgery improves head and neck cancer treatment 3113 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 1Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 2Too Few Cancer Survivors Pursue Healthy Lifestyles 18009 3Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 1Media Alert 3A 100 Black Men of Atlanta Host 3rd Annual Community Health Fair 18006 2InfoLogix Announces First Quarter 2008 Financial Results 18003 1InfoLogix Announces First Quarter 2008 Financial Results 18003 2InfoLogix Announces First Quarter 2008 Financial Results 18003 3InfoLogix Announces First Quarter 2008 Financial Results 18003 4InfoLogix Announces First Quarter 2008 Financial Results 18003 5InfoLogix Announces First Quarter 2008 Financial Results 18003 6InfoLogix Announces First Quarter 2008 Financial Results 18003 7InfoLogix Announces First Quarter 2008 Financial Results 18003 8InfoLogix Announces First Quarter 2008 Financial Results 18003 9
... MARKHAM, ON, June 28, 2007 /PRNewswire/ - Cytoch...se I clinical trial of,CTA018 Injection. The initi...A018 was safe and well tolerated. Complete study,r... completed Phase I trial was an open label,placeb...,administered to 20 healthy volunteers. In this tr...
... WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 -...rity owned subsidiary of,Accentia Biopharmaceutica... blinded interim data from the start of its fast-t...TM) for Non-Hodgkin,s,lymphoma (NHL) from Septembe...a is the most recent data that has been made avail...
Other Medicine Technology:Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 2Cytochroma Reports Positive Phase I Clinical Data for CTA018,Injection 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: